Stryker Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SYK research report →
About the company
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions.
- CEO
- Kevin A. Lobo
- IPO
- 1980
- Employees
- 53,000
- HQ
- Portage, MI, US
Price Chart
- Market Cap
- $121.37B
- P/E
- 36.30
- P/S
- 4.81
- P/B
- 5.28
- EV/EBITDA
- 21.72
- Div Yield
- 1.09%
- Gross Margin
- 63.67%
- Op Margin
- 21.34%
- Net Margin
- 13.21%
- ROE
- 15.10%
- ROIC
- 9.63%
- Revenue
- $25.12B · 11.16%
- Net Income
- $3.25B · 8.45%
- EPS
- $8.49 · 8.02%
- Op Income
- $4.89B
- FCF YoY
- 22.83%
- 52W High
- $404.87
- 52W Low
- $281.00
- 50D MA
- $311.73
- 200D MA
- $349.84
- Beta
- 0.79
- Avg Volume
- 2.50M
Get TickerSpark's AI analysis on SYK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 1, 26 | Stiles Spencer S | other | 1,607 |
| May 28, 26 | Fletcher Robert S | sell | 120 |
| May 28, 26 | Fletcher Robert S | sell | 165 |
| May 28, 26 | Fletcher Robert S | sell | 2,809 |
| May 28, 26 | Fletcher Robert S | sell | 1,067 |
| May 28, 26 | Fletcher Robert S | sell | 258 |
| May 28, 26 | Fletcher Robert S | sell | 125 |
| May 26, 26 | STRYKER RONDA E | sell | 3,707 |
| May 26, 26 | STRYKER RONDA E | sell | 21,807 |
| May 26, 26 | STRYKER RONDA E | sell | 115,960 |
Our SYK coverage
Recent articles, reports, and earnings notes.
Stryker (SYK): Premium Medtech Growth, Rich Valuation
Stryker is executing well with double-digit revenue growth, strong segment momentum, and raised 2026 EPS guidance. The stock remains a Buy, but the premium valuation argues for patience on pullbacks.
Medtronic may have finally found its second act
Medtronic finally has a growth story that looks big enough to matter at the company level, not just in a niche product line. With cardiac ablation surging and valuation still well below faster-loved device peers, MDT looks like the more compelling catch-up trade here.
Boston Scientific’s selloff is what a real medtech reset looks like
Boston Scientific’s plunge looks like a real reset, not a bargain-bin overreaction. Management already cut 2026 growth guidance, then reinforced that Watchman weakness is tied to a worsening procedure mix that the market can’t just wave away.
Want a deeper read on SYK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.